Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0893 Combination Therapy in Type 2 Diabetes
NCT00631488Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0893 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels. Started Feb 2008; status: completed.
02
Drugs
MK-0893
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00631488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00631488.